MetaCap

CytomX Therapeutics (CTMX) vs Kamada (KMDA)

Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.

Summary

Kamada (KMDA) has outperformed CytomX Therapeutics (CTMX) over the past year, gaining 14.7% versus a loss of 47.7%. Over five years, KMDA leads with a +22.7% price change compared with -69.9% for CTMX. Kamada is the larger company by market cap ($446.8 million vs $442.5 million), about 1.0 times the size.

Kamada pays a dividend yielding 7.24%, while CytomX Therapeutics does not currently pay one. Kamada converts more of its revenue into profit, with a net margin of 11.2% versus -22.8%.

Summary generated from market data by MetaCap's automated system. Methodology

Relative performance

CTMX-47.68%KMDA+14.67%
+80%+11%-58%
Nov 21, 20251 yearNov 20, 2026
CTMX-72.34%KMDA+38.21%
+66%-18%-101%
Nov 15, 20215 yearsNov 16, 2026

Percent change in share price from the first common trading day shown; excludes dividends.

Head-to-head

CTMX versus KMDA key metrics
MetricCTMXKMDA
Share price$2.03$7.74
Market cap$442.55M$446.85M
1-day change-0.98%-1.15%
YTD return-52.35%+9.63%
1-year return-47.68%+14.67%
5-year return-69.93%+22.66%
P/E ratio (TTM)—20.37
Forward P/E—13.34
EPS (TTM)$-0.51$0.38
Dividend yield0.00%7.24%
Annual dividend$0.00$0.56
Revenue (latest FY)$76.20M$180.46M
Revenue growth (YoY)-44.82%+12.12%
Net income (latest FY)$-17.37M$20.20M
Gross margin—42.34%
Operating margin-29.35%14.54%
Net margin-22.79%11.19%
52-week high$8.21$9.35
52-week low$1.87$6.63
Distance from 52-week high-75.27%-17.22%
Analyst consensusstrong_buystrong_buy
Avg. price target upside+509.85%+77.65%
Average volume4.27M121.87K
Shares outstanding218.00M57.73M
Employees69462
SectorHealth CareHealth Care
IndustryBiotechnology: Pharmaceutical PreparationsBiotechnology: Pharmaceutical Preparations

Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.

Key differences

  • KMDA has outperformed CTMX by 62.3 percentage points over the past year.
  • Kamada offers a meaningfully higher dividend yield (7.24% vs 0.00%).
  • Kamada is more profitable, keeping 11.2 cents of every revenue dollar as net income versus -22.8 cents for CytomX Therapeutics.
  • Kamada grew revenue faster in its latest fiscal year (+12.12% vs -44.82%).

About CytomX Therapeutics

CTMX stock →

CytomX Therapeutics, Inc. operates as an oncology-focused biopharmaceutical company that focuses on developing potent biologics designed to treat tumor microenvironment.

Health Care · Biotechnology: Pharmaceutical Preparations · 69 employees

About Kamada

KMDA stock →

Kamada Ltd. manufactures and sells plasma-derived protein therapeutics.

Health Care · Biotechnology: Pharmaceutical Preparations · 462 employees

CTMX vs KMDA FAQ

Which is bigger, CytomX Therapeutics or Kamada?

Kamada (KMDA) is larger, with a market capitalization of $446.85M compared with $442.55M for CytomX Therapeutics (CTMX).

Which stock has performed better over the past year, CTMX or KMDA?

KMDA returned +14.67% over the past 12 months, compared with -47.68% for CTMX (price return, excluding dividends). Past performance does not predict future results.

Which pays a higher dividend, CytomX Therapeutics or Kamada?

Kamada pays a dividend yielding 7.24%, while CytomX Therapeutics does not currently pay a regular dividend.

Are CytomX Therapeutics and Kamada in the same industry?

Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.

More comparisons